Class summary at a glance.

Every drug in the P2Y12 Platelet Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $1.29Bcombined across class
Total Rx claims: 22.5M7.0M unique beneficiaries
Generic mfrs (active): 39across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ticagrelor

Brand: BRILINTA · 1.5M Part D claims (CY24) · 445K beneficiaries · First FDA approval: 2011-08-05

17 generic mfrs 0 plans require PA

Low NADAC$0.321

→

Avg plan cost$1.11

Part D spend $1.00B 3× spread, current vs floor

Class share

78%

of class CY24 spend

View profile →

Clopidogrel Bisulfate

Brand: CLOPIDOGREL · 20.5M Part D claims (CY24) · 6.4M beneficiaries · First FDA approval: 2012-05-17

15 generic mfrs 0 plans require PA

Low NADAC$0.048

→

Avg plan cost$2.34

Part D spend $243.7M 49× spread, current vs floor

Class share

19%

of class CY24 spend

View profile →

Prasugrel

Brand: Effient · 510K Part D claims (CY24) · 170K beneficiaries · First FDA approval: 2017-07-12

6 generic mfrs 0 plans require PA

Low NADAC$0.289

→

Avg plan cost$0.300

Part D spend $38.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cangrelor

Brand: KENGREAL · — Part D claims (CY24) · First FDA approval: 2015-07-08

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clopidogrel

Brand: Plavix · — Part D claims (CY24) · First FDA approval: 1997-11-17

Brand-only (no generics) 0 plans require PA

Low NADAC$0.048

→

Avg plan cost$1.83

Part D spend — 38× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.